BackExagen Overview

Exagen Total Liabilities

Latest total liabilities for XGN: $40M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$39.72M
↑ 5.28% YoYΔ $1.99M vs prior year quarter

Peer average

Loading

Exagen Total Liabilities History

Loading

Exagen vs. peers: Total Liabilities Comparison

Loading

Exagen Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Exagen (XGN) FAQ

As of the most recent data (June 2026), XGN shows a total liabilities of $40M. That compares with $38M in the prior-year period — up 5.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, XGN's total liabilities is now $40M (was $38M) — a 5.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Exagen is outperforming or lagging.

Tracking XGN's total liabilities over time shows whether Exagen is scaling, shrinking, or reshaping that part of the business. The current reading is $40M That compares with $38M in the prior-year period — up 5.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Exagen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $40M) with ownership activity and broader fundamentals.

Exagen's total liabilities is $40M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.